We are still transitioning from our old blog, so pardon our dust. To contact the Mesothelioma Applied Research Foundation or for immediate help with your questions, you can reach us by phone at 877.363.6376.
Adding immunotherapy to chemotherapy plus bevacizumab shows promising benefit in survival for non-epitheliod mesothelioma patients, but not across the board
The phase 3 clinical trial known as BEAT-meso, which combines chemotherapy plus bevacizumab with immunotherapy, has shown an improvement in overall survival (OS) and progression-free
